Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Carcinoma, Non-Small-Cell Lung 50Small Cell Lung Carcinoma 23Breast Neoplasms 17Sarcoma 15Carcinoma, Hepatocellular 10Lung Neoplasms 9Esophageal Squamous Cell Carcinoma 9Stomach Neoplasms 8Neoplasms 8Triple Negative Breast Neoplasms 7Ovarian Neoplasms 7Nasopharyngeal Carcinoma 7Neoplasm Metastasis 6Pancreatic Neoplasms 5NSCLC 5Colorectal Neoplasms 5Carcinoma 5Uterine Cervical Neoplasms 4Thyroid Neoplasms 4Pheochromocytoma 4Esophageal Neoplasms 4Endometrial Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Ovarian Epithelial 4Recurrence 3Paraganglioma 3Non-squamous Non-small Cell Lung Cancer 3Glioma 3Fallopian Tube Neoplasms 3Cholangiocarcinoma 3

Interventions

Temozolomide 156Bevacizumab 69Radiotherapy 61Magnetic Resonance Spectroscopy 59Irinotecan 31Surgical Procedures, Operative 23Radiation 23Carboplatin 23Specimen Handling 20Carmustine 20Nivolumab 19Biopsy 17Lomustine 15Aminolevulinic Acid 15Radiotherapy, Intensity-Modulated 13Cyclophosphamide 13trametinib 12pembrolizumab 12Radiosurgery 12Erlotinib Hydrochloride 12fluorodopa F 18 11Topotecan 11Everolimus 11Blood Specimen Collection 11X-Rays 10IL13-PE38 10dabrafenib 9Etoposide 9ribociclib 8poly ICLC 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Glioma × anlotinib × Clear all
NCT04197492 2024-01-05

Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas

Huashan Hospital

Phase 2 Unknown
22 enrolled
CNS

Glioma

NCT04822805 2021-03-30

A Study of Anlotinib in the Treatment of Recurrent High-grade Glioma

First People's Hospital of Hangzhou

Phase 2 Unknown
27 enrolled
CNS

Glioma

NCT04668508 2020-12-16

Anlotinib to Malignant Brainstem Glioma

Zhejiang Cancer Hospital

Phase 2 Unknown
25 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡